Partners and Sponsors
Thank you to all our partners and sponsors supporting the WCC 2024.
If you are interested in sponsorship activities, please contact partnerships@uicc.org.
2024 World Cancer Congress
IN COOPERATION WITH
World Health Organization (WHO)
Founded in 1948, WHO is the United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health.
WHO leads global efforts to expand universal health coverage. We direct and coordinate the world’s response to health emergencies. And we promote healthier lives – from pregnancy care through old age. Our Triple Billion targets outline an ambitious plan for the world to achieve good health for all using science-based policies and programmes.
International Agency for Research on Cancer (IARC)
IARC’s Mission: Cancer research for cancer prevention
The International Agency for Research on Cancer (IARC) is the specialized cancer agency of the World Health Organization.
The objective of the IARC is to promote international collaboration in cancer research. The Agency is inter-disciplinary, bringing together skills in epidemiology, laboratory sciences and biostatistics to identify the causes of cancer so that preventive measures may be adopted and the burden of disease and associated suffering reduced. A significant feature of the IARC is its expertise in coordinating research across countries and organizations; its independent role as an international organization facilitates this activity. The Agency has a particular interest in conducting research in low and middle-income countries through partnerships and collaborations with researchers in these regions.
Causes and prevention of cancer
Emphasis is placed on elucidating the role of environmental and lifestyle risk factors and studying their interplay with genetic background in population-based studies and appropriate experimental models. This emphasis reflects the understanding that most cancers are, directly or indirectly, linked to environmental factors and thus are preventable. The IARC Monographs Programme is a core element of the Agency’s portfolio of activities, with international expert working groups evaluating the evidence of the carcinogenicity of specific exposures. The Agency is also committed to studying approaches for the early detection of cancer and in evaluating prevention strategies.
A global reference for cancer information
The IARC has an important role in describing the burden of cancer worldwide, through co-operation with and assistance to cancer registries and in monitoring geographical variations and trends over time. Key publications include the Cancer Incidence in Five Continents series and GLOBOCAN.
The classification of human tumours as reported in the WHO “Blue Book” series is an additional resource of value to cancer researchers and clinicians worldwide. In all cases the Agency strives to make its findings available to the widest possible audience.
Global cancer biobank
One of the products of IARC’s coordinating role is an increasingly important biobank with currently approximately 6 million samples from 600 000 subjects in total. This resource permits the application of innovative laboratory-based methodologies to study the causes, early detection and prevention of cancer through collaborative studies with many international partners.
Education and training
A core part of the Agency’s mission is education and training of cancer researchers worldwide. This is achieved through fellowships, courses and publications. Priority is given to training researchers from low and middle-income countries in the areas of cancer epidemiology and cancer registration.
Producing evidence-based science for global cancer control policies
The close working relationship between IARC and its parent organization, WHO, allows the research findings of the Agency to be translated effectively into timely policies for cancer control. This is manifest, for example, in co-operation in terms of reduction in tobacco use, implementation of vaccination against viruses associated with cancer causation, or in assessing the effectiveness of intervention strategies. IARC is not involved directly in implementation of control measures, nor does it conduct research on treatment or care of cancer patients.
International Atomic Energy Agency (IAEA)
The IAEA’s aim is to help build Member States’ capacities to support them in establishing high-quality health care worldwide. Nuclear technology plays a key role in the diagnosis and treatment of cancer. Over the past six decades, the IAEA has gained strong technical expertise and experience in the delivery of nuclear medicine and radiotherapy technology to Member States, contributing to the fight against cancer. Its support ranges from nutrition interventions, cancer diagnosis and treatment, quality assurance for the use of radiation in medicine for safe and accurate treatment of conditions such as cancer. The IAEA also assists Member States with the coordination of research projects, expert guidance, imPACT Reviews, resource mobilization, the development of internationally harmonized guidelines and supporting the development of strategic documents, training, and knowledge exchange, safety and quality.
Geneva Convention Bureau
Geneva, a dynamic hub of knowledge linking local experts in key industry sectors
The Geneva Convention Bureau is proudly supporting the organisation of the World Cancer Congress.
International Geneva Welcome Centre (CAGI)
Founded by the Swiss Confederation and the Republic and Canton of Geneva, the International Geneva Welcome Centre is the single entry point for the support and integration of employees of International Geneva and their families, NGOs and visiting delegates.
République et Canton de Genève
The République et Canton de Genève is proudly supporting the organisation of the World Cancer Congress.
Swiss Confederation
The Swiss Confederation is proudly supporting the organisation of the World Cancer Congress.
ORGANISED BY
Union for International Cancer Control (UICC)
The Union for International Cancer Control's (UICC) rapidly increasing membership base of over 1200 organisations in 172 countries, represents the world’s major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners.
In the last decade, we have reached millions of people with World Cancer Day, welcomed more than 15,000 delegates at our World Cancer Congresses, and launched four new organisations: the International Cancer Control Partnership, the McCabe Centre for Law & Cancer, City Cancer Challenge Foundation and the NCD Alliance.
IN PARTNERSHIP WITH
ACT - Alliance Contre le Tabac
The ACT-Alliance against tobacco is a non-profit association of public interest serving public health. For more than 30 years, it has brought together the main French organizations involved in the fight against tobacco.
Founded in 1991 by Prof. Maurice Tubiana following the entry into force of the Evin law, of which he was one of the main architects, ACT, advocates for advanced legal and policy measures of prevention at national and international levels.
In a society where information sources are multiplied and knowledge easily distorted, ACT is committed to shed light on the manipulations of this industry and to be a leading voice in protecting all present and future generations.
Through its federative action, ACT is mobilizing decision-makers, public health, environmental, human rights and financial actors, as well as the media, to ensure a Tobacco Free Generation in France by 2032.
Cancer Research UK (CRUK)
Cancer Research UK is the world’s largest independent funder of cancer research. Its vision is to bring forward the day when all cancers are cured. Since 1902 CRUK has found new ways to prevent, diagnose and treat cancer. CRUK-funded scientists’ pioneered early radiotherapy, developed some of the world’s top cancer drugs and discovered the tumour suppressor gene, p53. Its work has saved millions of lives across the world. CRUK invests $500m annually in world-leading research across all 200 different types of cancer, working with partners in Europe, North America and Asia to accelerate research progress. It provides information to those affected by cancer, works to increase cancer awareness, and uses its powerful, independent voice to keep cancer at the top of the political agenda. CRUK funds some of the world’s leading experts in tobacco research and is a key player in international tobacco control. It became a full UICC member in 1986.
Cancerfonden
The Swedish Cancer Society has a vision of a society in which fewer people get cancer and more people are cured or are able to lead long lives, enjoying a good quality of life. Together, we are helping to give more people a better future.
Our mission: How we are beating cancer faster together
· We enable new discoveries that speed up the work of beating cancer
· We help to shorten the path from research results to improved outcomes
· We create broad engagement to beat cancer faster together
· We use the knowledge and insights of people affected by cancer to develop and improve our work
The Swedish Cancer Society is working to ensure that Sweden achieves the following targets by 2030:
PREVENTION
Fewer people getting cancer. A 30% reduction in preventable cancer.
EARLY DETECTION
A third of all cancer detected at an earlier stage.
CURE
80% surviving a cancer diagnosis.
LIVING WELL
Everyone living with and after a cancer diagnosis enjoying a good quality of life.
Dutch Cancer Society (KWF)
KWF Kankerbestrijding/KWF Dutch Cancer Society was founded in 1949. Back then, the prognosis for cancer patients was bleak: 5 years post-diagnosis, only 1 out of 4 cancer patients was still alive. Nowadays, this number has increased to 2 out of 3 . We thank our donors, whose generous donations has enabled researchers to detect, understand and treat cancer better.
However, despite these promising numbers, our task is not finished. The increasing complexity of oncology is accompanied by new challenges and questions. If more cancer patients can be cured, or survive longer, how can we optimize their quality of life? How can we stimulate better treatment for rare and hard-to-treat tumours? And how can we prevent cancer?
The patient is key
Through our actions, we support patients in every aspect of their life. For people who have not yet been diagnosed with cancer, as well as for patients who can’t be cured.
Our main goals are:
• To prevent cancer wherever we can.
• To stimulate better treatment for every type of cancer.
• To aim for a better quality of life for (recovered) patients and their loved ones.
• To ensure that high quality palliative care is available for all patients.
Through stimulation of focused scientific research, policy making, knowledge transfer and collaboration with our stakeholders, KWF is dedicated to improving the lives of cancer patients and their loved ones. Our organisational structure enables us to respond quickly to developments in society and research..
There are enormous challenges ahead of us. KWF can’t face these alone. Therefore, we join forces with (inter)national stakeholders to achieve our goals. With the support of society, which includes 100,000 volunteers and almost 1 million donors.
We work together for a better life with and without cancer; this is what we stand for!
Hôpitaux Universitaires de Geneve
The HUG: Care, Teaching, and leading-edge Research
The Geneva University Hospital (HUG) comprises eight public hospitals and two clinics. Theirs missions are to provide health care to the community in all medical specialties, to help train physicians and health professionals, and to conduct medical and clinical research. The HUG operate as a national reference centre for influenza, emerging viral infections, meningococcus, and transplant immunology, and are the national reference laboratory for histocompatibility. They are also a WHO Collaborating Centre in six areas, as well as Centres of Excellence in a number of sectors. The HUG treat 275,000 patients each year, with a capacity of 2,015 hospital beds, and employ 12.800 people.
For more information on publications visit https://www.hug.ch/publications-hug
www.hug.ch – presse-hug@hcuge.ch
References:
https://www.hug.ch/laboratoire-virologie/centre-national-reference-influenza-cnri
https://www.hug.ch/centre-maladies-virales-emergentes
http://www.meningo.ch/
https://www.hug.ch/nephrologie/unite-immunologie-transplantation
https://www.hug.ch/en-bref
https://www.hug.ch/centres
Norwegian Cancer Society
The Norwegian Cancer Society (NCS) is one of the largest organizations in Norway. It represents the voices of those affected by cancer. We have 135,000 members, 27 000 volunteers and 190 employees. All are dedicated to promoting cancer cause. NCS works continuously to improve society’s attitude to the prevention and treatment of cancer. We fight cancer locally, nationally and globally. Through research and preventive measures, information, support, advice and lobbying.
The Norwegian Cancer Society’s purpose is to work to prevent and fight cancer. And to improve quality of life for patients and their families. Our vision is «a life without cancer».
What we do?
1. Research funding. Funding research is our main priority. Research implies hope for a cure for cancer in the future. It also implies optimal and quality cancer treatment for patients through excellent cancer research in Norway.
2. Cancer prevention and international collaboration. Through our work on disseminating information and knowledge, along with initiating projects and supporting political advocacy campaigns, the NCS endeavours to contribute to reducing the number of cancer cases.
3. Cancer care. Our goal is to achieve optimal life quality for cancer patients and their families through information and intervention campaigns, projects and political advocacy. One of our major accomplishments in collaboration with the Norwegian health authorities has been the establishment of Vardesenter, centres catering for the needs of hospitalized cancer patients. Another important milestone has been providing additional support to patients and caregivers through the services of a «cancer coordinator».
4. Communication and fundraising. The Norwegian Cancer Society is in constant dialogue and communication with cancer patients, families and other relevant bodies through various channels. Our goals include fundraising to promote activities, and providing comprehensive and credible information on cancer and the various activities in our organization.
SUPPORTED BY
DIAMOND
La Roche-Posay
N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. Recommended by 90,000 dermatologists worldwide*, La Roche-Posay was created by a pharmacist in 1975. The brand is today present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin. The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer specifically. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Since 2019, the Fondation La Roche-Posay is also committed to improving the life of children with cancer and their families. In 2020, the brand went a step further in its commitment to protect the planet. Besides launching the first eco-designed tubes integrating cardboard, the brand announced a long-term plan to reduce its use of virgin plastic by 70% in 2025.
For additional information about La Roche-Posay, visit www.laroche-posay.com.
*source: survey on the dermocosmetic market carried out by iqvia and other partners (ipsos, tns) between september 2017 and august 2018 among dermatologists in 62 countries.
SILVER
Abbvie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.
Daiichi Sankyo
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. They provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, their company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of their 15,000 employees worldwide, they create innovative new and generic medicines and new methods of drug discovery and delivery. Daiichi Sankyo share a passion for innovation, as well as compassion for the patients around the world who are in need of their medicines.
BRONZE
American Society of Clinical Oncology (ASCO)
The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) are multidisciplinary, global oncology organizations with nearly 45,000 members in over 150 countries. Through research, education, and promotion of high-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is one of the world’s largest and most respected centers devoted exclusively to cancer patient care, research, education and prevention. Our mission is to eliminate cancer in Texas, the nation, and the world.
MD Anderson Profile
U.S. News & World Report's "Best Hospitals" rankings again named MD Anderson the #1 hospital for cancer care in the United States. The institution has been named one of the nation's top two hospitals for cancer care every year since the survey began in 1990.
Sanofi
Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
UE LifeSciences
At UE LifeSciences, we believe that early detection of cancer must be affordable, equitable and accessible to all. We’re an award-winning women’s health company that is developing and scaling innovative solutions to fight common cancers in women globally. Our non-invasive and easy to use hand-held tools enable healthcare providers to bring early detection of breast and cervical cancer to the women in their community, where they live and work. Our innovation has received Innovative Health Technology recognition from the World Health Organization and Global Women’s HealthTech Award from the World Bank in 2022. With headquarters in the United States, UE LifeSciences has presence in India and Malaysia.
US National Cancer Institute (NCI)
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. The NCI coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
World Child Cancer
World Child Cancer improves cancer diagnosis, treatment and care for some of the world's poorest children. We do this by creating twinning partnerships linking hospitals between developed and developing countries. These partnerships create a two-way transfer of expertise and skills to develop locally appropriate and affordable solutions to the problem of childhood cancer. We provide funding to support the twinning partnership including drugs, training and mentoring programmes, salaries, improvements to facilities, awareness campaigns and family support.
SUPPORTER
Canadian Partnership Against Cancer (CPAC)
The Canadian Partnership Against Cancer was created by the federal government in 2006 with funding through Health Canada to work with Canada’s cancer community to reduce the incidence of cancer, lessen the likelihood of Canadians dying from cancer, and enhance the quality of life of those affected by cancer. As the steward of the Canadian Strategy for Cancer Control, the Partnership works with partners to reduce the burden of cancer for Canadians. Visit www.partnershipagainstcancer.ca
Jhpiego
Cancer Awareness Campaigns: Jhpiego work in country programs to conduct community outreach and education campaigns for cervical cancer prevention. The awareness campaigns are targeted to women in the catchment areas where VIA and Cryotherapy services have been set up. Advocacy and awareness campaigns have been conducted in Ghana (in collaboration with Rotary Club), Malawi, Philippines, Thailand, Guyana, etc. Jhpiego also participates in and receives funding support from the Tour of Hope, which raises funds for education and healthcare support for the prevention and treatment of cervical cancer in Asia. Cancer Prevention: Jhpiego provides technical assistance to countries for the introduction and expansion of cervical cancer prevention programs, with a focus on the Single Visit Approach, which combines screening with Visual Inspection with Acetic Acid (VIA), with the offer of Cryotherapy at the same visit. Jhpiego implements comprehensive prevention programs, taking into account advocacy and policies, training, service delivery, referral systems, community education, and monitoring and evaluation. Jhpiego is currently implementing programs Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines. Jhpiego has also implemented programs in Ghana and Malawi. Several Cancer Research & Publications. Education & Training: Jhpiego has organized and conducted three Regional VIA and Cryotherapy Clinical Training Courses; two in Asie (Thailand, Philippines) and one in Africa (Malawi). In addition, as a component of ongoing programs, Jhpiego routinely provides VIA and Cryotherapy training and follow up supervision and coaching support for health care providers Ghana, Malawi, Peru, Guyana, Indonesia, Ivory Coast, Mozambique, South Africa, Tanzania, Thailand and the Philippines.
WHO Regional Office for Europe
WHO is the authority responsible for public health within the United Nations system. The WHO Regional Office for Europe (WHO/Europe) is one of WHO’s six regional offices around the world. It serves the WHO European Region, which comprises 53 countries, covering a vast geographical region from the Atlantic to the Pacific oceans.
Ambassadors
2022 World Cancer Congress Sponsors